ABO不同型血浆输注的风险认知与临床实践进展OACSTPCD

Plasma transfusion is clinically used to replenish clotting factors and correct coagulopathy,playing an important role in the treatment of massive hemorrhage.Universal plasma and low titer group O whole blood can improve the timeliness and accessibility of urgent transfusions in patients with major bleeding.The strategy of ABO non-identical plasma transfusion,in the form of active and passive transfusion,has been extensively adopted in clinical practice.Active transfusion mainly includes group AB and A plasma;passive transfusion,on the other hand,involves the transfusion of low titer group O whole blood and ABO non-identical platelets.However,hemolysis and circulating immune complex formation are recognized to be the risks associated with transfusion of ABO non-identical plasma.Together,the risk-benefit trade-off with transfusion of non-ABO identical plasma deserves more attention and further exploration.